BTK inhibitorFDA-approvedInvestigational
Ibrutinib
How it works
Blocks the BTK enzyme, which is involved in B-cell receptor signaling and cancer growth.
Cancer types
Leukemia— All patients
Breast Cancer— All patients
Efficacy
In clinical trials, around 70% of patients achieved a complete or partial response, with a median progression-free survival of approximately 17 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Combination Treatments for High-Risk Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Cerebral Aspergillosis in Cancer Patients on Ibrutinib Therapy | Leukemia | observational | — | Source → |
| New Treatment Combination Tested in Younger Patients with Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Combination Therapy for Richter's Transformation | Leukemia | phase-2 | — | Source → |
| Testing Ibrutinib Alone or with Rituximab for Relapsed CLL | Leukemia | phase-2 | — | Source → |
| Study of Ibrutinib and Venetoclax for Chronic Lymphocytic Leukemia | Leukemia | preclinical | — | Source → |
| Exercise and CLL: A Study on Quality of Life | Leukemia | preclinical | — | Source → |
| Long-term Study of Ibrutinib for Various Blood Cancers | Leukemia | phase-3 | — | Source → |
| Comparing Treatments for Newly Diagnosed Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Testing Pevonedistat and Ibrutinib in Relapsed or Refractory CLL and Non-Hodgkin Lymphoma | Leukemia | phase-1 | — | Source → |
| Comparing Pirtobrutinib and Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Leukemia | phase-3 | — | Source → |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | Melanoma | phase-2 | — | Source → |
| Rapcabtagene Autoleucel and Ibrutinib for Blood Cancers | Leukemia | phase-1 | — | Source → |
| Nemtabrutinib vs Ibrutinib or Acalabrutinib for First-Line CLL/SLL Treatment | Leukemia | phase-3 | — | Source → |
| Ibrutinib Shows Promise in Treating Rare Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Treating Older Adults with Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Customizing Ibrutinib Treatment for Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Combination Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Leukemia | phase-1 | — | Source → |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Ibrutinib Therapy Linked to Atrial Fibrillation in CLL Patients | Leukemia | observational | — | Source → |
| Rare Fungal Infection Found in CLL Patients on Ibrutinib | Leukemia | observational | — | Source → |
| Combining Ianalumab with Ibrutinib Improves CLL Outcomes | Leukemia | preclinical | 38.5% of patients achieved a complete response or complete response with incomplete marrow recovery at cycle 9. | Source → |
| Pirtobrutinib Shows Promise in Treating Chronic Lymphocytic Leukemia | Leukemia | phase-3 | The overall response rate was 87.0% with pirtobrutinib versus 78.5% with ibrutinib. | Source → |
| Combination Therapy Fails to Improve CLL Response, but Activates CD8 T Cells | Leukemia | phase-2 | There was 1 complete response and 9 partial responses in 10 patients evaluable for response. | Source → |
| Optimizing Ibrutinib Doses for Chronic Lymphocytic Leukemia | Leukemia | phase-1/2 | Dose reductions based on response depth or toxicity preserved comparable response rates and progression-free survival to standard dosing. | Source → |
| Researchers Test New Skin Cancer Treatment Using Tiny Lipid Carriers | Melanoma | lab-study | — | Source → |
| Ibrutinib Treatment Outcomes in High-Risk CLL/SLL Patients | Leukemia | observational | — | Source → |
| CLL Treatments May Increase Heart Risks | Leukemia | review | — | Source → |
| New Study Compares Heart Risks of CLL Treatments | Leukemia | observational | The incidence of AF/flutter was lower for acalabrutinib compared to ibrutinib [5.8% vs. 11.7%]; the incidence of HTN was also lower in the acalabrutinib cohort [15% vs. 26.3%]. | Source → |
| Zanubrutinib vs Ibrutinib for Chronic Lymphocytic Leukemia: Cost Comparison | Leukemia | phase-3 | Treating 8 patients with zanubrutinib instead of ibrutinib prevented 1 progression or death. | Source → |
| Ibrutinib Treatment Affects CLL Cells and Immune System | Leukemia | lab-study | — | Source → |
| Ibrutinib and Acalabrutinib Show Different Effects on CLL Cells | Leukemia | lab-study | — | Source → |
| Ibrutinib May Worsen Inflammation in CLL Patients | Leukemia | lab-study | — | Source → |
| Rare CLL Relapse Manifests as Spinal Cord Infiltration | Leukemia | observational | — | Source → |
| Ibrutinib Resistance in CLL Patients May Not Affect Immune Response | Leukemia | lab-study | — | Source → |
| New Study Compares Safety of Two Cancer Drugs | Leukemia | observational | Atrial fibrillation or flutter occurred in 7.1% of patients with acalabrutinib and 14.7% of patients with ibrutinib. | Source → |
| CLL Patients Retreated after Ibrutinib Plus Venetoclax May Avoid Resistance Mutations | Leukemia | phase-2 | — | Source → |
| Many elderly leukemia patients stop taking ibrutinib treatment | Leukemia | observational | — | Source → |
| Genetic Factors Linked to Heart Problems in CLL Patients Taking Ibrutinib | Leukemia | observational | — | Source → |
| Comparing Zanubrutinib and Ibrutinib for Leukemia Treatment | Leukemia | meta-analysis | — | Source → |
| Testing for CLL Genes May Not Be Worth the Cost in Australia | Leukemia | phase-3 | Strategy 1 was associated with 5.69 quality-adjusted life-years (QALYs) and cost 458,836 Australian dollars (AUD). | Source → |
| Comparing Two Leukemia Treatments in Real-World Patients | Leukemia | observational | Acalabrutinib-treated patients were 89% more likely to initiate next treatment (hazard ratio = 1.89; p = 0.016). | Source → |
| One-third of CLL patients relapsing on ibrutinib have unmutated BTK and PLCG2 | Leukemia | observational | — | Source → |
| Combining two drugs may help some patients with rare cancer complication | Leukemia | phase-2 | The overall response rate was 42%. | Source → |
| Ibrutinib's Effect on Chronic Lymphocytic Leukemia in British Columbia | Leukemia | observational | The 2-year overall survival was 83.9% and event-free survival was 76.1%. | Source → |
| Ibrutinib Sensitizes Colorectal Cancer Cells to Ferroptosis | Colorectal Cancer | lab-study | — | Source → |
| Bleeding risk with ibrutinib and dermatologic procedures | Leukemia | observational | — | Source → |
| Ibrutinib's Effect on CLL Patients on Hemodialysis | Leukemia | observational | — | Source → |
| Australian and New Zealand Patients Benefit from Ibrutinib Treatment | Leukemia | observational | Ibrutinib provided a median of 47 months clinical benefit for participants with CLL/SLL and 14 months clinical benefit for those with MCL. | Source → |
| Combining CAR T cells and ibrutinib for chronic lymphocytic leukemia treatment | Leukemia | phase-2 | At 12 months, 72% of patients tested had no measurable residual disease (MRD). | Source → |
| New Mutation Found in CLL Patients on Zanubrutinib Treatment | Leukemia | lab-study | — | Source → |
| Combining Two Medicines Shows Promise in Treating Blood Cancers | Leukemia | phase-1 | The overall response rate was 32%. | Source → |
| Monitoring Ibrutinib Levels in Cancer Patients | Leukemia | lab-study | — | Source → |
| Ibrutinib May Be a Better First-Line Treatment for High-Risk CLL Patients | Leukemia | observational | The weighted high-risk ibrutinib group had a significantly longer time to next treatment (TTNT) than the weighted high-risk CIT group, with a hazard ratio of 0.5 (0.3-0.6), P < 0.010. | Source → |
| New Compounds Show Promise in Treating Melanoma | Melanoma | lab-study | The IC value in B16 cells was almost 9-fold better than that of ibrutinib. | Source → |
| Combining Ibrutinib with Other Treatments for CLL | Leukemia | review | — | Source → |
| Desensitization to Ibrutinib May Help Some Patients | Leukemia | observational | — | Source → |
| Understanding Ibrutinib's Effect on Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Eye Inflammation Linked to Ibrutinib Treatment for Leukemia | Leukemia | observational | — | Source → |
| Combining Ibrutinib with Standard Treatment for Pancreatic Cancer Does Not Improve Survival | Pancreatic Cancer | phase-3 | The overall response rate was 29% in the ibrutinib arm and 42% in the placebo arm. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.